{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:48:02Z","timestamp":1777891682226,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NRE"],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:p>BACKGROUND: Multiple sclerosis (MS) is the most common neurologic disease in young adults. Spasticity is one of its most disabling symptoms, with botulinum toxin A type A (BoNT-A) being one of the treatments of choice for this symptom. OBJECTIVE: We assessed the response to abobotulinumtoxinA in improving walking ability and fatigue in patients with spastic paraparesis caused by MS. METHODS: We performed a real-world, multicenter, prospective, open-label low-intervention trial in 84 patients with MS and spastic paraparesis of the lower limbs infiltrated with abobotulinumtoxinA (LINITOX study). The response of spasticity, walking ability and fatigue is analyzed in 4 cycles of ultrasound-guided injection in the lower limbs. RESULTS: The patients improved their walking ability by an average of 11.34% meters measured with 6-Minute Walk Test (6MWT), and decreased the percentage of fatigue by 6.86% (4.66 percentage points less), in the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) 4 weeks after abobotulinumtoxinA injection, both values are statistically significant. This improvement seems to persist over time, throughout the cycles. CONCLUSION: We found improved walking ability and less fatigue in patients with MS-related spastic paresis of the lower limbs after injection of abobotulinumtoxinA.<\/jats:p>","DOI":"10.3233\/nre-240038","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:18:45Z","timestamp":1718363925000},"page":"663-675","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of repeated injections of botulinum toxin A on gait and fatigue in adults with spastic paraparesis secondary to multiple sclerosis"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0867","authenticated-orcid":false,"given":"Ar\u00e1nzazu","family":"V\u00e1zquez-Doce","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Garc\u00eda","family":"Delgado","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Arriaza G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda P\u00eda","family":"Spottorno Rubio","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Meca","family":"Lallana","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz del Rio","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Bosch-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Sport Traumatology, Hospital San Rafael, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ot\u00f3n V\u00e1zquez","family":"Doce","sequence":"additional","affiliation":[{"name":"Laboratori Nazionali di Frascati INFN, Frascati, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Ortega","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed Tapiador","family":"Juan","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/NRE-240038_ref2","first-page":"CD012732","article-title":"Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews","volume":"1","author":"Amatya,","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/NRE-240038_ref3","unstructured":"Arriaza G\u00f3mez, M. J. (2023). Resultados de salud, funcionalidad y fatiga de un programa estructurado de reentrenamiento al esfuerzo en pacientes con esclerosis m\u00faltiple. [Tesis doctoral]. Universidad Aut\u00f3noma de Madrid. https:\/\/repositorio.uam.es\/handle\/10486\/706699."},{"key":"10.3233\/NRE-240038_ref4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/B978-0-444-63916-5.00015-X","article-title":"Balance, gait, and falls in multiple sclerosis","volume":"159","author":"Cameron,","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.3233\/NRE-240038_ref5","doi-asserted-by":"crossref","unstructured":"Cerda, A. L. (2014). Manejo del trastorno de marcha del adulto mayor, 25(2), 265\u2013275.","DOI":"10.1016\/S0716-8640(14)70037-9"},{"issue":"3","key":"10.3233\/NRE-240038_ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/nmt-2022-0002","article-title":"Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap","volume":"12","author":"Chan,","year":"2022","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.3233\/NRE-240038_ref7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/NRE-131021","article-title":"Meaningful improvement in walking performance after Botulinum Neurotoxin A (BoNT-A) in chronic spastic patients. Parente R, editor","volume":"34","author":"Cioncoloni,","year":"2014","journal-title":"NeuroRehabilitation"},{"issue":"3","key":"10.3233\/NRE-240038_ref8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/ene.14110","article-title":"Italian consensus on treatment of spasticity in multiple sclerosis","volume":"27","author":"Comi,","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.3233\/NRE-240038_ref9","unstructured":"Correa-Diaz, E. P. , J\u00e1come-S\u00e1nchez, E. , Torres-Herr\u00e1n, G. , Masabanda-Campa\u00f1a, L. , Ba\u00f1o-Jim\u00e9nez, G. , Altamirano-Brito, M. J. , Santos-Saltos, D. , Caiza-Zambrano, F. , Ortega Heredia, A. , Paredes Gonz\u00e1lez, V. , Garc\u00eda Castillo, M. A. , Guill\u00e9n-L\u00f3pez, F. (2018). Prognostic Factors In Multiple Sclerosis Rev. Ecuat. Neurol, 27(1)."},{"issue":"2","key":"10.3233\/NRE-240038_ref10","doi-asserted-by":"crossref","first-page":"e2468","DOI":"10.1097\/MD.0000000000002468","article-title":"Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity","volume":"95","author":"Dashtipour,","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.3233\/NRE-240038_ref11","first-page":"CD009689","article-title":"Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity","volume":"6","author":"Demetrios,","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.3233\/NRE-240038_ref12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","article-title":"Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force","volume":"264","author":"Dressler,","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.3233\/NRE-240038_ref13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","article-title":"Immunological aspects of botulinum toxin therapy","volume":"17","author":"Dressler,","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"10.3233\/NRE-240038_ref14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/21679169.2020.1775888","article-title":"The effectiveness of interventions targeting spasticity on functional clinical outcomes in patients with multiple sclerosis: a systematic review of clinical trials","volume":"24","author":"Ergul,","year":"2022","journal-title":"European Journal of Physiotherapy"},{"key":"10.3233\/NRE-240038_ref15","doi-asserted-by":"crossref","first-page":"576117","DOI":"10.3389\/fneur.2020.576117","article-title":"Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport\u00a0\u00ae) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies","volume":"11","author":"Esquenazi,","year":"2020","journal-title":"Front Neurol"},{"issue":"10","key":"10.3233\/NRE-240038_ref16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/pmrj.12517","article-title":"Long-term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity","volume":"13","author":"Esquenazi,","year":"2021","journal-title":"PM R"},{"key":"10.3233\/NRE-240038_ref17","unstructured":"Feldman, R. G. , Young, R. R. , Koella, W. P. Eds. (1980) Spasticity: Disordered Motor Control. [Yearbook], Chicago, 185\u2013204. https:\/\/search.worldcat.org\/es\/title\/spasticity-disordered-motor-control\/oclc\/6734642."},{"issue":"3","key":"10.3233\/NRE-240038_ref18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.12202","article-title":"Spasticity in patients with multiple sclerosis \u2013 clinical characteristics, treatment and quality of life","volume":"129","author":"Flachenecker,","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.3233\/NRE-240038_ref19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0269215517745348","article-title":"A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis","volume":"32","author":"Fu,","year":"2018","journal-title":"Clin Rehabil"},{"key":"10.3233\/NRE-240038_ref20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators.","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/NRE-240038_ref21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/1352458507082607","article-title":"Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls","volume":"14","author":"Goldman,","year":"2008","journal-title":"Mult Scler"},{"key":"10.3233\/NRE-240038_ref22","unstructured":"Harb, A. , Kishner, S. , Modified Ashworth Scale. (2024) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554572\/."},{"issue":"10","key":"10.3233\/NRE-240038_ref23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hch105","article-title":"What drives quality of life in multiple sclerosis?","volume":"97","author":"Hemmett,","year":"2004","journal-title":"QJM"},{"issue":"6","key":"10.3233\/NRE-240038_ref24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","article-title":"Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study","volume":"68","author":"Hyman,","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"60","key":"10.3233\/NRE-240038_ref25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)","volume":"14","author":"Hobart,","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/NRE-240038_ref26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijge.2018.05.005","article-title":"Post-stroke Spasticity: A Review of Epidemiology, Pathophysiology, and Treatments","volume":"12","author":"Kuo,","year":"2018","journal-title":"International Journal of Gerontology"},{"issue":"Suppl 2","key":"10.3233\/NRE-240038_ref27","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s10072-008-0950-1","article-title":"Physiopathology of fatigue in multiple sclerosis","author":"Leocani,","year":"2008","journal-title":"Neurol Sci"},{"key":"10.3233\/NRE-240038_ref28","volume-title":"Handbook of Clinical Neurology","author":"Marsden,","year":"2023"},{"key":"10.3233\/NRE-240038_ref29","unstructured":"Miguens, X., Cordero, C., De Miguel, C. (2023) Toxina botul\u00ednica en Rehabilitaci\u00f3n. Gu\u00eda de pr\u00e1ctica cl\u00ednica. Artes Gr\u00e1ficas Rupem."},{"issue":"1","key":"10.3233\/NRE-240038_ref30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13548500802241902","article-title":"Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support","volume":"14","author":"Motl,","year":"2009","journal-title":"Psychol Health Med"},{"issue":"14","key":"10.3233\/NRE-240038_ref31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/toxins14110774","article-title":"Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis","volume":"9","author":"Novarella,","year":"2022","journal-title":"Toxins (Basel)"},{"issue":"3","key":"10.3233\/NRE-240038_ref32","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.rehab.2021.101579","article-title":"Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis","volume":"65","author":"Ojardias,","year":"2022","journal-title":"Ann Phys Rehabil Med"},{"issue":"11","key":"10.3233\/NRE-240038_ref33","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/1352458516643600","article-title":"Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper","volume":"22","author":"Otero-Romero,","year":"2016","journal-title":"Mult Scler"},{"issue":"9","key":"10.3233\/NRE-240038_ref34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0269215513480956","article-title":"Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial","volume":"27","author":"Paoloni,","year":"2013","journal-title":"Clin Rehabil"},{"issue":"2","key":"10.3233\/NRE-240038_ref35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7224\/1537-2073.2022-115","article-title":"Recognition, Description, and Variability of Spasticity in Individuals With Multiple Sclerosis and Potential Barriers to Clinician-Patient Dialogue: Results From SEEN-MSS, a Large-Scale, Self-Reported Survey","volume":"26","author":"Thrower,","year":"2024","journal-title":"Int J MS Care"},{"key":"10.3233\/NRE-240038_ref36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mehy.2017.03.011","article-title":"Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity?","volume":"102","author":"Trompetto,","year":"2017","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.3233\/NRE-240038_ref37","doi-asserted-by":"crossref","first-page":"jrm00133","DOI":"10.2340\/16501977-2770","article-title":"Upper Limb International Spasticity-III (ULIS-III) study group. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study","volume":"53","author":"Turner-Stokes,","year":"2021","journal-title":"J Rehabil Med"},{"issue":"3","key":"10.3233\/NRE-240038_ref38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey,","year":"1995","journal-title":"Qual Life Res"},{"issue":"14","key":"10.3233\/NRE-240038_ref39","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton,","year":"2020","journal-title":"Mult Scler"}],"container-title":["NeuroRehabilitation"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/NRE-240038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:08:59Z","timestamp":1777615739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/NRE-240038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/nre-240038","relation":{},"ISSN":["1053-8135","1878-6448"],"issn-type":[{"value":"1053-8135","type":"print"},{"value":"1878-6448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}